GLP-1 Agonists

GLP-1 helps regulate glucose control, insulin control, satiety, and weight. Semaglutide and tirzepatide improve blood sugar regulation and metabolic health, supporting sustainable weight management. The article acknowledges real clinical benefits and weight loss effects from GLP-1 drugs. Semaglutide demonstrated a 20% reduction in major cardiovascular events in obese patients with existing cardiovascular disease. GLP-1 drugs improve blood pressure, triglycerides, insulin sensitivity, and near-term risks for coronary disease, dementia, and breast cancer. Saxenda and Victoza are both liraglutide but have different target doses, titration endpoints, and injection pens, making them a safety-critical distinction especially during drug shortages. GLP-1 medications are classified by peptide backbone — either exendin-4 (derived from Gila monster venom) or human GLP-1. Among those with specialist visits during follow-up, GLP-1 RA patients averaged 15 specialist visits compared with 5 for SGLT2i patients, a disparity largely reflecting the longer median follow-up in the GLP-1 RA cohort. GLP-1 agonists represent the most significant therapeutic advance in metabolic medicine in decades. Akker…